文献速递消化道肿瘤与早癌消化内镜

小腺瘤与微小腺瘤对后续进展期肿瘤的预测价值

The predictive value of small versus diminutive adenomas for subsequent advanced neoplasia.
PubMed 文献 · Gastrointest Endosc · 2019-09-13

该回顾性队列研究纳入2477例基线结肠镜发现1-9mm低级别管状腺瘤且无进展期腺瘤的患者,随访至少200天。结果显示6-9mm腺瘤患者进展期肿瘤绝对风险为6.9%,高于1-5mm腺瘤患者的3.6%(P=.001),提示现行指南应基于小腺瘤与微小腺瘤进行风险分层。

要点

  • 基线6-9mm腺瘤患者随访进展期肿瘤风险为6.9%,显著高于1-5mm腺瘤的3.6%。
  • ≥5个腺瘤且至少1个为6-9mm者风险最高,达10.4%。
  • 筛查结肠镜亚组中,各腺瘤数量组伴6-9mm腺瘤均与进展期肿瘤风险升高相关。

核心结论

  • 基线小腺瘤(6-9mm)患者随访进展期肿瘤风险高于仅微小腺瘤(1-5mm)患者。
  • 术后监测指南应考虑基于小腺瘤与微小腺瘤进行风险分层。

研究设计与样本

  • 单中心美国学术中心结肠镜数据库的回顾性评估。
  • 纳入基线结肠镜显示1-9mm低级别管状腺瘤且无进展期腺瘤的患者,随访结肠镜至少200天后评估进展期肿瘤。

主要发现

  • 2477例合格基线结肠镜中,异时性进展期肿瘤绝对风险从1-5mm腺瘤的3.6%升至至少1个6-9mm腺瘤的6.9%(P=.001)。
  • ≥5个腺瘤且至少1个为6-9mm者随访进展期肿瘤风险最高,为10.4%(P=.006)。
  • 仅考虑筛查结肠镜时,1-2个、3-4个、≥5个腺瘤伴6-9mm腺瘤的进展期肿瘤风险OR分别为4.07(95%CI 1.50-11.04)、4.91(95%CI 1.44-16.75)、4.71(95%CI 1.30-17.05)。

关键数值与推荐

  • 进展期肿瘤定义为癌、高级别上皮内瘤变、腺瘤≥10mm或绒毛状成分。
  • 基线腺瘤尺寸分组:1-5mm为微小腺瘤,6-9mm为小腺瘤。

临床怎么用

  • 对基线6-9mm腺瘤患者,尤其合并≥5个腺瘤时,应视为进展期肿瘤高风险人群。
  • 现行指南将所有1-9mm低级别管状腺瘤同等对待,本研究支持按小腺瘤与微小腺瘤分层制定监测间隔。

局限性

  • 单中心回顾性研究,可能存在选择偏倚和信息偏倚。
  • 随访结肠镜至少200天,但未明确统一随访间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with previous colorectal adenomas are at increased risk of colorectal cancer. Current guidelines for postpolypectomy surveillance intervals treat all tubular adenomas 1 to 9 mm in size with low-grade dysplasia as carrying the same level of risk. We evaluated whether 6 to 9 mm adenomas detected at colonoscopy are associated with greater risk of advanced neoplasia at follow-up compared with baseline 1 to 5 mm adenomas. METHODS: We retrospectively evaluated a colonoscopy database at a single U.S. academic center. Patients with baseline examinations demonstrating tubular adenomas 1 to 9 mm in size with low-grade dysplasia and no advanced adenomas were included. Follow-up colonoscopies were performed at least 200 days later and were assessed for incident advanced neoplasia (cancer, high-grade dysplasia, adenoma ≥10 mm in size, or villous elements). RESULTS: There were 2477 qualifying baseline colonoscopies. The absolute risk of metachronous advanced neoplasia increased from 3.6% in patients with 1 to 5 mm adenomas to 6.9% in patients with at least 1 adenoma of 6 to 9 mm (P = .001). Patients with 5 or more adenomas 1 of which was at least 6 to 9 mm had the highest risk of advanced neoplasia at follow-up (10.4%, P = .006). When only screening colonoscopies were considered, all baseline groups (1-2 adenomas, 3-4 adenomas, ≥5 adenomas) with adenomas 6 to 9 mm in size had an increased risk for metachronous advanced neoplasia (odds ratio [OR], 4.07; 95% confidence interval [CI], 1.50-11.04; OR, 4.91; 95% CI, 1.44-16.75; OR, 4.71; 95% CI, 1.30-17.05, respectively). CONCLUSIONS: Patients with baseline small (6-9 mm) adenomas have an increased risk of advanced lesions on follow-up compared with patients with only diminutive (1-5 mm) adenomas. Postpolypectomy guidelines should consider risk stratification based on small versus diminutive adenomas.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hartstein JD, Vemulapalli KC, Rex DK, et al. The predictive value of small versus diminutive adenomas for subsequent advanced neoplasia. Gastrointest Endosc. 2019. PMID: 31525360. doi:10.1016/j.gie.2019.08.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。